Predictive role of 17α-hydroxy-progesterone serum levels of response to follicle-stimulating hormone in patients with abnormal sperm parameters.


Journal

Fertility and sterility
ISSN: 1556-5653
Titre abrégé: Fertil Steril
Pays: United States
ID NLM: 0372772

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 07 06 2023
revised: 19 09 2023
accepted: 19 09 2023
medline: 28 11 2023
pubmed: 26 9 2023
entrez: 25 9 2023
Statut: ppublish

Résumé

To study the possible role of serum 17α-hydroxy-progesterone (17αOH-P) levels in predicting favorable responses to follicle-stimulating hormone (FSH) administration in patients with normal serum FSH levels and idiopathic abnormal sperm parameters. Prospective cohort study. University-affiliated fertility center. Fifty patients with oligozoospermia, asthenozoospermia, and/or teratozoospermia and normal serum levels of gonadotropins and total testosterone (TT). Treatment with exogenous FSH is administered subcutaneously at a dose of 150 IU 3 times a week for 3 consecutive months. Luteinizing hormone levels, FSH levels, TT levels, 17αOH-P levels, testicular volume, conventional sperm parameters, and seminal spermatid concentration were evaluated before and after therapy. To evaluate the predictive role of pretreatment serum 17αOH-P levels on FSH responsiveness, the doubling of sperm concentration at the end of the FSH administration was considered a positive outcome. After therapy, patients showed a significant increase in sperm concentration, total sperm count (TSC), progressive motility, percentage of normal forms, FSH levels, TT levels, and testicular volume. There was a negative correlation between pretreatment 17αOH-P levels and the posttreatment increase in sperm concentration, TSC, progressive motility, and normal morphology, and a positive correlation with the posttreatment increase in spermatids. Predictive analysis showed that 17αOH-P levels (<1.18 ng/mL) foretold a doubling of sperm concentration with a sensitivity of 90.0% and a specificity of 73.3%, and of TSC with a sensitivity of 91.3% and a specificity of 81.48%. The results of this study suggest that pretreatment serum levels of 17αOH-P, a marker of steroidogenic function, appear to be able to predict the success of subcutaneous administration of exogenous FSH in terms of spermatogenesis improvement. Receiver operating characteristic curves indicated that 17αOH-P levels (<1.18 ng/mL) predict a doubling of sperm concentration and TSC after exogenous FSH administration to patients with idiopathic abnormal sperm parameters and normal gonadotropin levels.

Identifiants

pubmed: 37748551
pii: S0015-0282(23)01879-4
doi: 10.1016/j.fertnstert.2023.09.013
pii:
doi:

Substances chimiques

Follicle Stimulating Hormone 9002-68-0
Progesterone 4G7DS2Q64Y
Follicle Stimulating Hormone, Human 0
Testosterone 3XMK78S47O
17-alpha-Hydroxyprogesterone 68-96-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1193-1202

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests R.C. has nothing to disclose. R.A.C. has nothing to disclose. C.G. has nothing to disclose. V.G. has nothing to disclose. A.A. has nothing to disclose. A.E.C. has nothing to disclose. S.L.V. has nothing to disclose.

Auteurs

Rossella Cannarella (R)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Rosita A Condorelli (RA)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Carmelo Gusmano (C)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Vincenzo Garofalo (V)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Antonio Aversa (A)

Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro.

Aldo E Calogero (AE)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Electronic address: aldo.calogero@unict.it.

Sandro La Vignera (S)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH